You are here

Eli Lilly

Lilly cancer drug pipeline hit by trial setback

Lilly cancer drug pipeline hit by trial setback

Biopharma Dive

pancreatic cancer

ARMO BioSciences

Flag link:

Eli Lilly to shutter neuroscience R&D center next year

Eli Lilly to shutter neuroscience R&D center next year

Fierce Biotech

Flag link:

FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades

Xconomy

Flag link:

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Lilly touts Cyramza lung cancer data, as AZ’s Tagrisso grows even more powerful

Fierce Pharma

EGFR lung cancer

Flag link:

FDA approves Pfenex's osteoporosis therapy

FDA approves Pfenex's osteoporosis therapy

Yahoo/Reuters

Flag link:

Judge Dismisses ‘White Coat’ Whistleblower Allegations Against Bayer, Eli Lilly

Judge Dismisses ‘White Coat’ Whistleblower Allegations Against Bayer, Eli Lilly

BioSpace

whistleblower lawsuits

Flag link:

Eli Lilly to voluntarily delist from Euronext Paris exchange

Eli Lilly to voluntarily delist from Euronext Paris exchange

Marketwatch

Flag link:

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Mom approved: J&J, Takeda and more lead Working Mother's best places to work list for 2019

Fierce Pharma

Flag link:

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

How Big Can This $8 Billion-Plus Diabetes Drug Class Get?

Motley Fool

Flag link:

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Sanofi, AZ, Lilly and more win business in China's expanded cut-price purchase program

Fierce Pharma

Flag link:

Sigilon Therapeutics approaches the clinic

Sigilon Therapeutics approaches the clinic

EP Vantage

Flag link:

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

Investors Business Daily

oral semaglutide

Flag link:

Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed

Half-Off Sale! Five Major Drugmakers Reveal Vast Gross-to-Net Price Gaps—and Why Rebate Reform Is Still Needed

Drug Channels

Flag link:

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J nears FDA nod

Fierce Pharma

Boehringer Ingelheim

Flag link:

Factbox: Britain's insulin providers prepare for Brexit fallout

Factbox: Britain's insulin providers prepare for Brexit fallout

Yahoo/Reuters

Flag link:

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

RAPS.org

Flag link:

ICER dings Novo's new oral diabetes drug

ICER dings Novo's new oral diabetes drug

Biopharma Dive

oral semaglutide

Boehringer Ingelheim

Flag link:

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More

Xconomy

Blueprint Medicines

Flag link:

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Fierce Biotech

non-small cell lung cancer

Flag link:

4 Biotech Stocks With Big Catalysts in September

4 Biotech Stocks With Big Catalysts in September

Motley Fool

Mirati Therapeutics

Pralsetinibdicines

Flag link:

Pages